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Abstract: The PD-1/PD-L1 axis has emerged as a significant target in cancer 
immunotherapy. Current medications include monoclonal antibodies, which have shown 
impressive clinical results in the treatment of several types of tumors. The cocrystal 
structure of human PD-1 and PD-L1 is expected to be a valuable starting point for the 
design of novel inhibitors, alongside with the recent crystal structures with monoclonal 
antibodies, small molecules and macrocycles.  
 
Significance The FDA-approved monoclonal antibodies targeting the PD-1 / PD-L1 axis 
have revolutionized the field of cancer immunotherapy. The recent increase in structural 
data both for small molecules and macrocycles targeting PD-1 or PD-L1 will provide 
valuable tools for the rational design of novel drugs against this protein-protein interaction. 
 
1. Introduction: PD-1/PD-L1 Pathway 
The development of cancer is monitored by the immune system. Most tumors are 
eliminated by the process of immune surveillance. In this process, T-cells play a major 
role; their activation stimulates an immune response against cancer cells. The T-cell 
activation requires two signals: a specific peptide epitope of the antigen must be presented 
on the major histocompatibility complex (MHC) of an antigen-presenting cell (APC) and 
it must form a complex with the T-cell receptor. A second signal occurring from the 
interaction of co-stimulatory molecules of activation is necessary. In the absence of co-
stimulatory molecules, T cells enter the unresponsive state of clonal anergy (1).Tumors 
tend to evade immuno-surveillance by down-regulating both MHC and co-stimulatory 
molecules and also up-regulating co-inhibitory molecules (2). Mechanistic hallmarks by 
which tumors avoid immune surveillance are called immune checkpoints or co-inhibitory 
pathways and recently, they have emerged as a promising approach in cancer 
immunotherapy. 
Programmed death-1 / PD-1 (or CD279) is such a member of the class of immune 
checkpoint receptors. It is a member of the B7-CD28 family of receptors (3). By binding 
on either of its two ligands PD-L1 (known also as CD274 or B7-H1) and PD-L2 (known 
also as CD273, B7-DC or PDCD1LG2) a co-inhibitory signal is delivered (4). PD-1 is a 
55-kDa monomeric type I surface transmembrane glycoprotein. The protein is composed 
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of an extracellular IgV domain, a transmembrane domain and an intracellular cytoplasmic 
domain, which contains two tyrosine-based immunoreceptor signaling motifs; the 
inhibitory motif (ITIM) and the switch motif (ITSM) (5-7). Both motifs, upon PD-1 
engagement can be phosphorylated and in turn recruit Src homology region 2 domain-
containing phosphatase-1 (SHP-1) and SHP-2 (8). The 40-kDa PD-L1 and the 25-kDa PD-
L2 are both type I transmembrane proteins, containing extracellular IgV and IgC domains 
and a transmembrane domain. They lack an identifiable intracellular signaling domain (9). 
The two ligands share 37% identity with each other, but differ significantly in their affinity 
for PD-1 and their tissue specific expression. 
 
Table 1. PD-1/PD-L1 directed FDA approved monoclonal antibodies (www.fda.gov, last 
update 23/9/2017) 





September 4, 2014 unresectable or metastatic melanoma 
October 2, 2015 metastatic non-small lung cancer 
August 5, 2016 head and neck squamous cell carcinoma (HNSCC) 
October 24, 2016 non-small cell lung cancer (NSCLC) 
March 15, 2017 refractory classical Hodgkin lymphoma 
May 18, 2017 locally advanced or metastatic urothelial carcinoma 
May 23, 2017 
unresectable or metastatic, microsatellite instability-high 
(MSI-H) or mismatch repair deficient (dMMR) solid tumors 
September 22, 2017 
recurrent locally advanced or metastatic, gastric or 
gastroesophageal junction adenocarcinoma 
          Pembrolizumab 
(Keytruda®) 
with pemetrexed and 
carboplatin 
May 10, 2017 
previously untreated metastatic  non squamous non-small cell 
lung cancer (NSCLC) 
Nivolumab 
(Opdivo®) 
December 22, 2014 unresectable or metastatic melanoma 
March 4, 2015 metastatic squamous non-small cell lung cancer 
October 9, 2015 metastatic non-small cell lung cancer 
November 23, 2015 renal cell carcinoma (RCC) 
November 10, 2016 squamous cell carcinoma of the head and neck (SCCHN) 
May 17, 2016 Hodgkin lymploma 
February 2, 2017 locally advanced or metastatic urothelial carcinoma 
August 1, 2017 
mismatch repair deficient (dMMR) and microsatellite 





October 1, 2015 
 
BRAF V600 wild type unresectable or metastatic melanoma 
January 23, 2016 unresectable or metastatic melanoma 
Atezolizumab 
(Tecentriq™) 
          May 18, 2016 locally advanced or metastatic urothelial carcinoma 
October 18, 2016 metastatic non-small cell lung cancer (NSCLC) 
April 17, 2017 advanced bladder cancer 
Avelumab(Bavencio ®) 
March 23, 2017 metastatic Merkel cell carcinoma 
May 9, 2017 locally advanced or metastatic urothelial carcinoma 
Durvalumab(Imfinzi ®) May 1, 2017 locally advanced or metastatic urothelial carcinoma 
 
2. Antibodies approved and in development 
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Currently, there are both antibodies targeting PD-1 and antibodies targeting PD-L1 under 
clinical investigation either as monotherapy or in combinations with other immune 
checkpoint inhibitors, monoclonal antibodies, chemotherapy, vaccines and radiation. The 
first monoclonal antibodies targeting PD-1 approved by FDA in 2014 were pembrolizumab 
and nivolumab; both for the treatment of advanced melanoma. In table 1 an overview of 
mAbs in the field, approved by FDA is provided. Current focus in clinical trials aims to 
improve efficacy and patient response by searching for drug combinations and thus close 
to 1,000 clinical trials are ongoing just for checkpoint inhibitors targeting programmed cell 
death protein 1 (PD-1) and its ligand PD-L1 (10).  
3. Biomarkers for PD1-PD-L1 
Following the clinical success of immune checkpoint inhibitors, the establishment of 
biomarkers in immunotherapy has emerged as an imperative need. Although dramatic 
survival benefits mostly for patients with melanoma and less in other types of cancers are 
observed, a rather small percentage of patients currently respond to PD1-PDL1 directed 
treatments. Therefore, biomarkers play a crucial role in predicting the likelihood of a 
patient’s response, understanding the mechanisms of action and avoiding immune-related 
adverse effects (irAEs). Cancer biomarkers have been successfully established in cases of 
KRAS mutation, HER2 expression and estrogen receptor expression just to name a few. 
Currently, PD-L1 is under investigation as a predictive biomarker of response for PD-
1/PD-L1 immunotherapy. 
In a recent study, PD-L1 tumor expression showed significant differences in different types 
of cancer. The over-expression of PD-L1 is correlated with better response to PD-1 / PD-
L1 inhibition in melanoma, non-small cell lung cancer (NSCLC) and renal cell carcinoma 
(RCC) (11). A meta-analysis, including data from 20 clinical trials for melanoma, lung 
cancer and genitourinary cancers showed that in the overall sample, a significant 
interaction was observed between PD-L1 expression and overall response rate (ORR), 
which was significantly higher in PD-L1 positive patients treated with nivolumab or 
pembrolizumab (12). Notably, however, clinical response has also been demonstrated in 
patients with PD-L1 negative tumors (13). 
Moreover, although the up-regulation of PD-L1 in selected solid tumors can be detected 
by immunohistochemistry (IHC) on both tumor and immune cells, confusion arises 
regarding the significance of this detection. PD-L1 is not present simultaneously on tumor 
and immune cells in all types of cancer (14). The fact that the expression of PD-L1 is 
inducible complicates the situation even further. Therefore, it is possible for PD-L1 to be 
expressed heterogeneously even within a patient’s tumor (11). So far, the methodologies 
used to evaluate PD-L1 status, differ significantly. Interestingly however, in October 2015, 
following the accelerated approval of pembrolizumab for metastatic NSCLC, FDA 
approved PD-L1 IHC 22C3 pharmDx (Dako North America), as the only predictive 
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companion diagnostic for selecting NSCLC patients for pembrolizumab. The test’s 
approval was based on an analysis showing that patients with at least 50% of their tumor 
cells expressing PD-L1 were most likely to respond to treatment. To observe the PD-L1 
expression space and time resolved clearly the potential of techniques other than 
immunohistochemistry such as for example the modern imaging technique positron 
emission tomography (PET) is required. 
Currently, the data concerning the potential establishment of PD-L1 as a single biomarker 
remain controversial. Alternative biomarker approaches, such as the quantification of 
tumor infiltrating lymphocytes (TILs), the identification of tumor neoantigens and the 
mutational load of the tumor biomarkers seem to offer a better correlation with the clinical 
outcomes (15). 
4. Is there a need for small molecules and other approaches beyond mAbs? 
There are several arguments why it is desirable to search for alternatives to mAbs in 
immunoncology. Generally, the production cost of mAbs remains extremely high. 
Moreover, the high molecular weight of mAbs, leads to poor diffusion, especially in large 
tumors. High affinity antibodies bind tightly to the antigen on first encounter, meaning that 
they remain on the periphery of the tumor, which is far from ideal for targeting solid 
tumors. Furthermore, the Fc portion of IgG antibodies can interact with various receptors 
on the surface of different cell types and thus affects their retention in the circulation (16). 
mAbs are immunogenic and can lead - albeit in rare cases - to irAEs sometimes with deadly 
outcome. The very long half-life times of PD-1 and PD-L1 directed mAbs can make irAEs 
difficult to treat. Small and medium sized molecules (such as macrocycles) can potentially 
overcome these issues. The significance of protein-protein interactions (PPIs) is well-
established and although targeting PPIs with small molecules can be challenging there are 
successful examples of small-molecule modulators of PPIs (17). 
5. Crystal structures of PD1-PDL1 and PD1-PDL2 
In 2008 the first high resolution crystal structure complexes regarding this PPI were 
published. The complex of murine PD-1 and human PD-L1 (PDB 3BIK) (18) and that of 
murine PD-1 and murine PD-L2 (PDB 3BP5) (19), established the structural foundations 
of the PD-1/PD-L1 and PD-1/PD-L2 interactions. These structures have not allowed, 
however, for assessment of the extent of plasticity in these interactions when starting from 
the apo-protein components of the complexes. The crystal structure of the extracellular 
domain of human PD-1 alone was determined in 2011 (PDB 3RRQ). 
Despite the fact that the murine PD-1 binds in vitro both to murine and human PD-L1, and 
human PD-1 binds to the PD-L1 of each species, it should be taken into account that the 
protein sequence identity between murine and human PD-1 is only 64% and between 
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murine and human PD-L1 is 77%. Thus, indicating likely differences in the details of the 
binding modes. This hypothesis was recently confirmed after Holak et al. (20) reported the 
crystal structure of the human PD-1/human PD-L1 complex (PDB 4ZQK, 5C3T), which 
indeed documents significant differences in the binding between murine and human PD-1 
and the ligand (hPD-L1). This information also allowed for the identification of features of 
three hot-spot pockets in human PD-1/PD-L1 required for inhibition of this interaction. 
PD-1 assumes a ß-sandwich immunoglobulin-variable (IgV)-type topology with Cys54 
and Cys123 forming a characteristic disulfide bridge; however, PD-1 lacks the second 
disulfide common to other family members (CD28, CTLA-4, and ICOS).  
Similarly to PD-1, the interacting, N-terminal domain of PD-L1 is also characterized by 
the Ig V-type topology. PD-1 and PD-L1 form a 1:1 complex within the crystal, in contrast 
to CTLA-4 complexes with its ligands, where both interacting partners form homodimers. 
The interaction of PD-1 and PD-L1 resembles that of Ig V domains within antibodies and 
T-cell receptors being mediated by the strands from the front faces of interacting domains 
(GFCC0 b sheets). 
In principle, the Å-resolution crystal structure of Holak et al. (20) provides a perfect 
starting point for the rational structure-based drug design (SBDD) of molecules against the 
protein-protein interaction (PPI). However, the interface between the two proteins is rather 
large (~1.700 Å2), hydrophobic and flat, without deep binding pockets, which makes the 
interface likely a difficult target for small molecules. Moreover, the hydrophobic interface 
also increases the chances to discover false positive hits considerably. Nonetheless, small 
molecule interrupters of PD1-PD-L1 have been described recently (see below).  
 
6. Cocrystal structures with monoclonal antibodies  
 
Recently, cocrystal structures of monoclonal antibodies targeting PD-1 or PD-L1 were 
described, shedding light to their molecular interactions.  
For pembrolizumab, an IgG4 antibody, the crystal structure of the full-length antibody was 
described (PDB 5DK3) (21). The complex of pembrolizumab Fab (antigen-binding 
fragment) with hPD-1 (PDB 5JXE) (22) revealed that the stoichiometry is 1:1. 
Furthermore, the structural superposition of this complex with the hPD-1/hPD-L1 shows 
the overlapping surface regions, indicating that the antibody can antagonize hPD-L1 by 
competing for binding to hPD-1.  One more crystal structure of pembrolizumab with hPD-
1 (PDB 5B8C) (23) was obtained in higher resolution. It is in good agreement with the 
previous one and provides additional data regarding the interfacial water molecules at the 
binding interface, which have an impact on both affinity and specificity of the interaction.  
Moreover, a comparison of the crystal structure of PD-1/nivolumab Fab complex (PDB 
5GGR) with PD-1/pembrolizumab (PDB 5GGS) (24) indicated that the epitopes of both 
antibodies occupy directly part of PD-L1 binding site and can thus outcompete PD-L1 for 
binding to PD-1. 
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Avelumab, an IgG1 antibody, utilizes in its complex with hPD-L1 (PDB 5GRJ) (25) both 
heavy (VH) and light chain (VL) to bind to the IgV domain of the PD-L1. The contribution 
of the light chain is greater than the heavy chain. Moreover, the binding epitope region of 
avelumab on hPD-L1 overlaps with the hPD-1 binding region, indicating that the partially 
overlapping pattern results to the blocking mechanism. 
For the anti-PD-L1 mAB durvalumab, the crystal structure was recently disclosed (PDB 
5XJ4). In this case both heavy and light chains contribute to the binding, resulting in steric 
clash which deters PD-L1 from binding to PD-1 (26). 
The crystal structure of PD-L1 with BMS-936559 Fab, a fully human IgG4 antibody 
currently in clinical trials, showed that its epitope occupies a large part of PD-1 binding 
site (PDB 5GGT) (24).  
In addition, in 2016 the cocrystal structure of an ultra-high-affinity engineered PD-1 mutant 
(HAC) with hPD-L1 was described (PDB 5IUS). This complex has a high degree of 
similarity with the hPD-1/hPD-L1. The main differences are observed in the β4-β5 loop. 
The high-affinity binding is driven by enthalpic gains, owning to the extensive polar 
contact network between the mutant and PD-L1 (27).  In 2017 a second high-affinitiy 
mutant PD-1 was described, bearing a single aminoacid substitution (A132L). This leads 
to an increase of van der Waals interactions (28).  
Furthermore, the crystal structure of a PD-L1 nanobody (single domain antibody) was 
published (PDB 5JDS). The nanobody KN035 competes with PD-1 for binding to PD-L1 
mainly through a single surface loop of 21 amino acids (29).  
In general, the binding mode seems to differ between PD-1 and PD-L1 mAbs (Figure 1). 
A more thorough analysis of the structural biology for PD-1/PD-L1 was recently performed 






Figure 1. Different interaction modes of PD(L)1. (A) Complex of hPD-1 (red) with hPD-
L1(blue) [PDB 4ZQK]. The amino acids in sticks represent the hotspots. The two residues in 
the red circle are Tyr68 of PD-1 (red) and Tyr123 of PD-L1 (blue). (B) Complex of PD-1 (red) 
with nivolumab Fab (yellow: light chain, purple: heavy chain) [PDB 5GGR]. (C) Complex of 
PD-L1 (blue) with avelumab Fab (purple: light chain, pink: heavy chain) [PDB 5GRJ]. (D) 
Complex (homodimer) of PD-L1 (blue) and BMS-08 (sticks, purple) [PDB 5J8O]. 
 
7. Cocrystal structures with small molecules  
Bristol-Myers Squibb (BMS) workers have disclosed small molecules binding to PD-L1 
(Scheme 1) (31). The scaffold consists of a tri-aromatic structure, including a mono-ortho 
substituted biphenyl substructure. Moreover, another phenyl ring is connected to the 
biphenyl and contains also a methylene amine moiety. The biological activity of the 
claimed compounds was established by a homogenous time-resolved fluorescence (HTRF) 
binding assay in which Europium cryptate-labeled anti-Ig was used. Typical examples are 
BMS-8, BMS-37, BMS-200 and BMS-202. No further in vitro or in vivo assays have been 
described supporting the biological activity of compounds based on the above-mentioned 
scaffold.  
The true nature of compounds BMS-202 and BMS-8 as PD-1/PD-L1 antagonists was 
recently rigorously proven by co-crystal structures with PD-L1 (PDB: 5J89, 5J8O 
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respectively) (32). The obtained crystals diffracted at 2.2 Å resolution. Four protein 
molecules found in the asymmetric unit were organized into two dimers with one inhibitor 
molecule located at the interface of each dimer. The inhibitor inserts deep into a cylindrical, 
hydrophobic pocket created at the interface of two monomers within the dimer. The pocket 
is open to the solvent on one side of the dimer and restricted by the sidechain of ATyr56 on 
the opposite side. Overall, the inhibitor-protein interaction is best described as bimodal, 
spatially divided into hydrophobic and electrostatic parts following the inhibitor bimodal 
design. 
Furthermore, Holak et al (33) disclosed two novel crystal structures of BMS-37 and BMS-
200. The crystals diffracted at 2.35 and 1.7Å respectively (PDB 5N2D, 5N2F). NMR 
experiments indicated that both compounds bind to PD-L1 and induce its oligomerization 
in solution. Interestingly, the crystal structures revealed notable differences (Figure 2). The 
binding mode of compound BMS-37 follows the one already observed for BMS-8 and 
BMS-202. All of them are examples of the (2-methyl-3-biphenylyl)-methanol scaffold. 
However, BMS-200, an example of [3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-
methylphenyl]-methanol scaffold induced a conformational change in ATyr56. The 2,3-
dihydro-1,4-benzodioxinyl group forces the ATyr56 to take a different position, thus 
turning the previously observed deep, hydrophobic cleft to a deep, hydrophobic tunnel and 
making part of the compound accessible to solvent. Two novel crystal structures were 
reported for the optimized derivatives BMS-1001 (PDB 5NIU) and BMS-1166 (PDB NIX) 
by Holak et al (34). These derivatives in particular showed significantly improved 
cytotoxic properties towards tested cell lines. Furthermore, it was proven that both BMS-
1001 and BMS-1166 have the potential to restore the activation of effector Jurkat T cells, 
although less effectively than the monoclonal antibodies. Nevertheless, these data highlight 
the potential of small molecules.  
Other small molecules have been claimed to antagonize PD1-PD-L1, however their mode-
of-action has not been rigorously proven so far. An overview of claimed PD-1/PD-L1 
inhibitors from patents is provided here (35). 
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Scheme 1. PD-1/PD-L1 inhibitors synthesized by BMS (Bristol-Myers Squibb Company). 
 




8. Macrocycles  
Several patents belonging to Bristol-Myers Squibb Company claim macrocycles that 
showed high affinity to PD-L1 at low concentrations (36). 
The majority of the described macrocycles contain either 14 or 13 amino acid residues 
[Scheme 2]. In most of them a linking sulphur atom is present and this is used as the starting 
point for the numbering of the amino acids. In another patent this suphur is replaced, either 
by oxygen or carbon.  
A comparison of the different structures with the 14-motif reveals that in most cases the 
first amino acid is unaltered as a neutral amide or bis-amide. The alterations include the 
addition of extra aromatic or aliphatic rings on the amide moiety, thus making this residue 
more hydrophobic. The second amino acid is frequently changed and varies from a 
hydrophobic isoleucine to polar amino acids, including aspartic acid, arginine, lysine, 
serine or threonine. Amino acids 3 and 4 are mostly constant as hydrophobic moieties with 
chains of butane. Moreover, the backbone nitrogens in positions 3 and 4 are in almost all 
cases methylated. In position 5 a tryptophan is usually present or if altered it is towards a 
benzothiophene, a dihydropyrrole ring or an indole ring bearing a carboxylic acid 
substitution. Morpholine or thiomorpholine also appear, but less frequently. A highly 
variable position among the patents is amino acid 6, which varies from polar (serine, lysine, 
tyrosine, aspartic acid, glutamic acid, glutamine) to hydrophobic (alanine, glycine). 
Position 7 is also highly constant as a tryptophan residue, whereas position 8 is almost 
always a proline or a hydroxylated proline. In position 9 a usual feature is isoleucine, but 
it could also vary towards polar residues (aspartic acid, glutamic acid, lysine, serine, 
asparagines, glutamine). Amino acid 10 also varies and usually it is a polar or basic residue 
(histidine, lysine, morpholine, hydroxy-pyrrole, serine, asparagine, glutamine). The next 
two amino acids are highly constant with a proline in position 11 and an asparagine in 
position 12 in almost all cases. This is followed by a hydrophobic residue in position 13, 
usually an alanine or a proline is present. The final position 14 is always aromatic and the 
most common feature is tyrosine. In some cases, there are also halogens or methoxy 
substituents on the phenyl ring, but it seems to be less common than the tyrosine.  
Regarding the macrocycles with 13 amino acids, the sulphur bond is always included, as 
well as the two proline residues in positions 5 and 10. Most likely the latter are responsible 
for making beta turns in the macrocycles. The main difference from the 14-motif is that 
there are 5 phenyl rings present (positions 3, 4, 6, 7, 12 and 13) and not three (positions 5, 
7 and 14). This feature makes these macrocycles more hydrophobic. Moreover, the tyrosine 
which is kept constant as the 14th amino acid here is always replaced with a phenyl ring 
with fluoro substituents. 
BMS macrocyclic peptides disrupting the PD-1/PD-L1 interaction were originally studied 
in HTRF assay (37). Holak et al (38) studied further these macrocycles with NMR, DSF, 
crystallography and also in a cell assay in order to determine their ability to restore T-cell 
function. The analysis included peptide-57 (15-mer), peptide-71 (14-mer) and peptide-99 
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(13-mer). Crystal structures were obtained for peptide-57 (PDB 5O4Y) and peptide-71 
(PDB 5O45) in a ratio peptide : PD-L1 1:1 (Scheme 3, figure 3).  The interaction is 
described as “face-on binding”. In both cases there is a partially overlap with PD-1 binding 
epitope and the binding is dominated by hydrophobic interactions and to a smaller extent 
polar interactions. Closer inspection of the interactions reveals significant differences 
between the peptides.  For peptide-57, two significant pockets are occupied with bulky 
indole side-chains, whereas for peptide-71 only one hydrophobic pocket is occupied with 
the side chain of phenylalanine. The polar interactions vary significantly between the two 
peptides, but in any case, the binding seems to be driven mainly by the hydrophobic 
interactions.. These novel crystal structures allow the comparison of the binding mode with 
monoclonal antibodies and provide valuable structural information for drug design.  
 
Scheme 2. Example of macrocycle with 14 amino acids (Bristol-Myers Squibb Company 
WO2014151634 A1 compound 16, Ki 5nM). The numbering of amino acids starts from the position 
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Scheme 3. 2D- Structures of peptide-57 (15-mer, left) and peptide-71 (14-mer, right)  
 
Figure 3. Binding of peptide-57 (15-mer, left) peptide-71 (14-mer, right) on PD-L1. 
9. Summary and Outlook  
Immune checkpoint inhibitors represent an exciting new field in cancer treatment. The 
disclosed crystal structures with monoclonal antibodies, small molecules and more recently 
macrocycles, have started to elucidate the molecular interactions.  
All these data taken together provide new tools for the rational design of small molecule 
inhibitors, macrocycles or middle-sized cyclic peptides that may have specific advantages 
compared to the already approved monoclonal antibodies.  
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